Antibody-drug conjugates (ADCs) are a class of therapeutics, in which synthetic drugs are attached to highly selective antibodies via specific linkers and conjugation methods.
First generation ADCs consist of cytotoxic drugs that are conjugated to antibodies via either random lysines or structurally disrupted disulfide bonds. Many have proven to be highly successful clinically and commercially, but the ADC field is increasingly focusing on next generation conjugation methods whereby the cytotoxic agents are attached to precise locations on the antibodies and do not disrupt the structurally important disulfide bonds.  The HoneyBear CoNectar™ technology achieves this goal and, in addition, is ideally suited to conjugate two distinct drugs onto a single antibody.  Such dual armed antibodies present an attractive opportunity for the next wave of innovative ADCs.
CoNectar™ is based on enzymatic addition of one or more payloads to a precise location on therapeutic antibodies – the conserved carbohydrates on the antibody Fc constant domain – a position that does not interfere with the critical antibody-antigen interactions.
Our business strategy is to utilize this powerful platform to develop and commercialize novel Antibody-Drug Conjugates (ADC) through licensing and co-development partnership with biotech or pharmaceutical companies.